Table 3.

Summary of studies of dry powder measles product presented to the expert group for stage II of the CHNRI process

Reference	Factor for investigation	Results	Conclusions
LiCalsi, C., et al [55]	Feasibility of dry powder inhalation in measles	Optimal vaccine delivery site – lungs; Particle sizing 1-5μm; Preparation – micronization and jet-milling ;3 Spiros delivery devices designed	Undemonstrable clinical application
de Swart, R.L., et al [56]	Dry powder vaccination in Macaques	Low seroresponse to measles dry powder blend compared to injection or liquid aerosol vaccination	Proof of principle evident by stimulation of weak immune response. Poor device design in macaque model – loss of vaccine at delivery.
LiCalsi, C., et al [57]	Dry powder measles vaccine potency retention	Up to 89% viral potency retention can be achieved with micronization.
Burger, J.L., et al [58]	Stabilizing dry powder measles formulations	Myo-inositol> trehalose as a sugar stabilizer in dry powder measles vaccinations	Myo-inositol is relatively unhygroscopic, improving its dry powder vaccination credentials